-
Views
-
Cite
Cite
E. Moreno Artero, N. Schinkel, S. Chaumon, I. Corset, T. Rabeony, C. Elie, N. Bellon, C. Bodemer, C. Greco, Efficacy of topical ropivacaine in children and young adults with hereditary epidermolysis bullosa, British Journal of Dermatology, Volume 184, Issue 3, 1 March 2021, Pages 550–552, https://doi.org/10.1111/bjd.19551
- Share Icon Share
Extract
Funding sources: this study was supported by Assistance Publique‐Hôpitaux de Paris.
Conflicts of interest: The authors declare no conflicts of interest.
E.M.A. and N.S. are joint first authors. C.B. and C.G. are joint last authors.
Dear Editor, Epidermolysis bullosa (EB) is a heterogeneous group of rare inherited skin disorders that cause fragile, blistering skin. There are four major types: EB simplex (EBS), junctional EB, dystrophic EB (DEB) and Kindler EB.1 The chronic wounds cause severe pain and has a major impact on quality of life.
No effective treatment is available and EB has implications for the psychological, physical and social wellbeing of the child and the family.2 Wound care and dressing change are the mainstay of treatment and aim to protect eroded skin from trauma and secondary infection. To minimize discomfort, dressings are removed in the bath or with wet compresses. Despite optimal nursing care, these procedures are painful and poorly tolerated with children developing major anxiety and phobia of baths.